Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18742917 | METHODS FOR DIFFERENTIATING DOPAMINERGIC NEURONS FROM STEM CELLS | June 2024 | November 2025 | Allow | 17 | 3 | 1 | No | No |
| 18668092 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | May 2024 | December 2025 | Allow | 19 | 5 | 0 | Yes | No |
| 18538999 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | December 2023 | December 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18082907 | REGENERATIVE CELL THERAPY FOR VIRAL INDUCED SEXUAL DYSFUNCTION | December 2022 | November 2024 | Abandon | 23 | 1 | 1 | No | No |
| 18000637 | HYPOXIA-RESISTANT NATURAL KILLER CELLS | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18056118 | LINCRNA-DEFICIENT NON-HUMAN ANIMALS | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18056145 | CANINE-SPECIFIC THERAPEUTIC COMPOSITIONS AND METHODS OF USE | November 2022 | June 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17960047 | REDUCTION OF NEUTROPHIL EXTRACELLULAR TRAP FORMATION BY MESENCHYMAL STEM CELLS AND THEIR EXOSOMES | October 2022 | August 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17953216 | PREPARATION, EXPANSION, AND USES OF ADULT PLURIPOTENT STEM CELLS | September 2022 | September 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17909939 | NOVEL USE OF CROSS-FLOW FILTRATION DEVICE FOR PREPARING FUNCTIONAL EXOSOME | September 2022 | March 2026 | Allow | 42 | 1 | 1 | No | No |
| 17760446 | METHODS AND COMPOSITIONS FOR IPSC-DERIVED MICROGLIA | August 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17845067 | EXOSOMES FOR THE TREATMENT OF INTERSTITIAL CYSTITIS | June 2022 | July 2025 | Allow | 37 | 3 | 0 | Yes | No |
| 17692790 | RECONSTRUCTING HUMAN EARLY EMBRYOGENESIS IN VITRO WITH PLURIPOTENT STEM CELLS | March 2022 | July 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17624084 | TRANSGENIC MAMMALS AND METHODS OF USE THEREOF | December 2021 | August 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17556880 | METHOD FOR PRODUCING HEPATOCYTE CULTURE, CELL-CONTAINING POROUS FILM, AND METHOD FOR IMPROVING OR MAINTAINING FUNCTION OF HEPATOCYTE OR HEPATIC PROGENITOR CELL | December 2021 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17552174 | ADENO ASSOCIATED VIRAL VECTOR DELIVERY OF ANTIBODIES FOR THE TREATMENT OF DISEASE MEDIATED BY DYSREGULATED PLASMA KALLIKREIN | December 2021 | February 2025 | Allow | 38 | 3 | 1 | Yes | No |
| 17619517 | EVALUATION METHOD OF CULTURE SUBSTRATE AND/OR CULTURE MEDIUM SOLUTION, AND USE OF EVALUATION METHOD | December 2021 | August 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17614110 | RECOMBINANT HERPESVIRALES VECTOR | November 2021 | November 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17612653 | MINIGENE THERAPY | November 2021 | April 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17595203 | COMPOSITIONS AND METHODS OF ACETYLCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17522619 | IN VITRO EQUINE MODEL SYSTEMS AND THEIR INTEGRATION INTO HORSE-ON-A-CHIP PLATFORM | November 2021 | July 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17605988 | ALLOGENEIC CAR-T CELL, PREPARATION THEREFOR, AND APPLICATION THEREOF | October 2021 | June 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17602963 | METHODS OF ANTI-TUMOR THERAPY | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17599979 | HTRA1 MODULATION FOR TREATMENT OF AMD | September 2021 | November 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17439714 | UNIFIED IN-VITRO PROCESS FOR OBTAINING LUNG CELLS FROM PLURIPOTENT STEM CELLS | September 2021 | October 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17438039 | IMPROVED PROCESS FOR INTEGRATION OF DNA CONSTRUCTS USING RNA-GUIDED ENDONUCLEASES | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17429295 | METHOD FOR CHARACTERISING A TISSUE-ENGINEERED CONSTRUCT | August 2021 | April 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17310424 | PARVOVIRAL VECTORS AND METHODS OF MAKING AND USE THEREOF | August 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17425148 | SYNP5 (PROA9), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL GANGLION CELLS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17377978 | METHODS AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS | July 2021 | September 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17421680 | LOCALIZED ADMINISTRATION OF RNA MOLECULES FOR THERAPY | July 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17420484 | NON-NATURALLY OCCURRING THERMOGENIC ADIPOCYTES, METHODS OF MAKING, AND METHODS OF USE THEREOF | July 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17418498 | POLYPEPTIDES USEFUL FOR GENE EDITING AND METHODS OF USE | June 2021 | February 2026 | Allow | 56 | 4 | 1 | Yes | No |
| 17415575 | MODIFIED ORTHOPOXVIRUS VECTORS | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17415628 | COMPOSITIONS AND METHODS FOR HIGHLY EFFICIENT GENETIC SCREENING USING BARCODED GUIDE RNA CONSTRUCTS | June 2021 | March 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17415440 | HYBRID PROMOTERS AND THEIR USES IN THERAPY, NOTABLY FOR TREATING TYPE II COLLAGENOPATHIES | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17414641 | CELL PORATION AND TRANSFECTION APPARATUSES | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17311306 | MATRIX ATTACHMENT REGIONS AND USES IN PROMOTING GENE EXPRESSION | June 2021 | November 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17299484 | VIRAL TRANSDUCTION USING POLOXAMINES | June 2021 | August 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17296049 | Hepatocyte Expansion Methods | May 2021 | August 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17325920 | DEVICE AND METHOD FOR THE EXTRACTION OF STEM CELLS FROM ADIPOSE TISSUE | May 2021 | May 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17321629 | CAR BASED IMMUNOTHERAPY | May 2021 | April 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17309208 | MEANS AND METHODS OF PREVENTING OR REVERSING AGING | May 2021 | December 2025 | Abandon | 55 | 2 | 1 | No | Yes |
| 17290446 | METHOD FOR PREPARING INTESTINAL TRACT CELL LAYER DERIVED FROM PLURIPOTENT STEM CELL | April 2021 | July 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17284908 | RNA-GUIDED TRANSCRIPTIONAL REGULATION AND METHODS OF USING THE SAME FOR THE TREATMENT OF BACK PAIN | April 2021 | February 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17210131 | LUX EXPRESSION IN CELLS AND METHODS OF USE | March 2021 | June 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17278280 | SURFACE MODIFIED EXTRACELLULAR VESICLES | March 2021 | January 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17278275 | CARGO LOADED EXTRACELLULAR VESICLES | March 2021 | December 2024 | Abandon | 45 | 1 | 0 | No | No |
| 16962828 | FIBER ASSEMBLY AND USE THEREOF | March 2021 | July 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 17277055 | THERAPEUTIC NANOPARTICLES AND METHODS OF USE THEREOF | March 2021 | January 2026 | Allow | 58 | 4 | 1 | Yes | No |
| 17276016 | PaCas9 nuclease | March 2021 | August 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17274029 | MEDIUM FOR DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELL, METHOD FOR PREPARING MESENCHYMAL STEM CELL BY USING SAME, AND MESENCHYMAL STEM CELL PREPARED THEREBY | March 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17274051 | ONCOLYTIC VIRUS PLATFORM TO TREAT HEMATOLOGICAL CANCER | March 2021 | November 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17273071 | Compositions and Methods for Improving Base Editing | March 2021 | July 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17271814 | SELF-INACTIVATING TRANSPOSASE PLASMIDS AND USES THEREOF | February 2021 | February 2026 | Allow | 59 | 2 | 1 | No | No |
| 17184238 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | February 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17250712 | OPTIMIZED PROMOTER SEQUENCES, INTRON-FREE EXPRESSION CONSTRUCTS AND METHODS OF USE | February 2021 | January 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17269450 | METHODS AND COMPOSITIONS FOR PRODUCING A VIRUS | February 2021 | March 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17178279 | METHODS OF EXPANDING EMBRYONIC STEM CELLS IN A SUSPENSION CULTURE | February 2021 | April 2024 | Allow | 37 | 1 | 0 | No | No |
| 17168311 | Preparation Method for Attenuated Rhabdovirus and Application Thereof | February 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17265750 | IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII | February 2021 | August 2025 | Allow | 54 | 3 | 0 | No | No |
| 17158797 | METHOD FOR PRODUCING INTESTINAL EPITHELIAL CELL AND INTESTINAL EPITHELIAL CELL | January 2021 | February 2026 | Abandon | 60 | 5 | 0 | Yes | No |
| 17155411 | CONCEPTS FOR THE TREATMENT OF GENETIC DISORDERS WITH HIGH-CAPACITY PLAL-GENERATED GOLD NANOPARTICLES | January 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17260791 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | January 2021 | October 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 17260365 | CELL LINKERS FOR HETEROTYPIC CELL SPHEROIDS | January 2021 | July 2024 | Abandon | 42 | 1 | 0 | Yes | No |
| 17260283 | COMPOSITIONS AND METHODS FOR GENERATING PHYSIOLOGICAL X CHROMOSOME INACTIVATION | January 2021 | January 2026 | Allow | 60 | 5 | 0 | Yes | No |
| 17260111 | COMPOSITIONS AND METHODS RELATED TO APTAMER-BASED REVERSIBLE CELL SELECTION | January 2021 | August 2025 | Allow | 55 | 2 | 2 | Yes | No |
| 16953849 | BIOCOMPATIBLE TEXTILE MESH AND TISSUE CONSTRUCTS FROM MANICARIA SACCIFERA, METHODS OF GROWING CELLS AND TISSUES, AND METHODS OF TREATING SUBJECTS WITH THE BIOCOMPATIBLE TEXTILE MESH AND TISSUE CONSTRUCTS | November 2020 | May 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17054474 | COMPOSITIONS AND METHODS FOR REDUCING SPLICEOPATHY AND TREATING RNA DOMINANCE DISORDERS | November 2020 | August 2025 | Abandon | 58 | 2 | 1 | No | No |
| 17054008 | CRISPR-cas9 SYSTEM AND USES THEREOF | November 2020 | April 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 16996302 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | August 2020 | May 2024 | Abandon | 45 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner EBBINGHAUS, BRIANA NOEL.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner EBBINGHAUS, BRIANA NOEL works in Art Unit 1632 and has examined 58 patent applications in our dataset. With an allowance rate of 39.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner EBBINGHAUS, BRIANA NOEL's allowance rate of 39.7% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by EBBINGHAUS, BRIANA NOEL receive 1.41 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by EBBINGHAUS, BRIANA NOEL is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +82.6% benefit to allowance rate for applications examined by EBBINGHAUS, BRIANA NOEL. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 57.1% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.7% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.